ALGS

Company Overview — What Does Aligos Therapeutics, Inc. Do?

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics, Inc. (ALGS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Lawrence M. Blatt and employs approximately 90 people. With a market capitalization of $48M, ALGS is one of the notable companies in the Healthcare sector.

Aligos Therapeutics, Inc. (ALGS) Stock Rating — Reduce (April 2026)

As of April 2026, Aligos Therapeutics, Inc. receives a Reduce rating with a composite score of 21.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ALGS ranks #3,302 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Aligos Therapeutics, Inc. ranks #502 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ALGS Stock Price and 52-Week Range

Aligos Therapeutics, Inc. (ALGS) currently trades at $8.00. The stock gained $0.05 (0.7%) in the most recent trading session. The 52-week high for ALGS is $13.69, which means the stock is currently trading -41.6% from its annual peak. The 52-week low is $3.76, putting the stock 112.6% above its annual trough. Recent trading volume was 25K shares, suggesting relatively thin trading activity.

Is ALGS Overvalued or Undervalued? — Valuation Analysis

Aligos Therapeutics, Inc. (ALGS) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.91x, versus the sector average of 2.75x. The price-to-sales ratio is 14.96x, compared to 1.66x for the average Healthcare stock.

At current multiples, Aligos Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Aligos Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Aligos Therapeutics, Inc. (ALGS) earns a quality factor score of 17/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -44.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -26.6% versus the sector average of -33.1%.

On a margin basis, Aligos Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -3387.3% (sector: -66.1%). Net profit margin stands at 1603.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -30.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ALGS Debt, Balance Sheet, and Financial Health

Aligos Therapeutics, Inc. has a debt-to-equity ratio of 65.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.90x, indicating strong short-term liquidity. Total debt on the balance sheet is $122,000. Cash and equivalents stand at $42M.

ALGS has a beta of 2.27, meaning it is more volatile than the broader market — a $10,000 investment in ALGS would be expected to move 127.0% more than the S&P 500 on any given day. The stability factor score for Aligos Therapeutics, Inc. is 19/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Aligos Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Aligos Therapeutics, Inc. reported revenue of $3M and earnings per share (EPS) of $-2.45. Net income for the quarter was $-24M. Gross margin was 100.0%. Operating income came in at $-86M.

In FY 2025, Aligos Therapeutics, Inc. reported revenue of $2M and earnings per share (EPS) of $-2.45. Net income for the quarter was $-24M. Revenue grew -39.5% year-over-year compared to FY 2024. Operating income came in at $-88M.

In Q3 2025, Aligos Therapeutics, Inc. reported revenue of $741,000 and earnings per share (EPS) of $-3.04. Net income for the quarter was $-32M. Revenue grew -40.7% year-over-year compared to Q3 2024. Operating income came in at $-28M.

In Q2 2025, Aligos Therapeutics, Inc. reported revenue of $965,000 and earnings per share (EPS) of $-1.53. Net income for the quarter was $-16M. Revenue grew -9.0% year-over-year compared to Q2 2024. Operating income came in at $-19M.

Over the past 8 quarters, Aligos Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $1M to $3M. Investors analyzing ALGS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ALGS Dividend Yield and Income Analysis

Aligos Therapeutics, Inc. (ALGS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ALGS Momentum and Technical Analysis Profile

Aligos Therapeutics, Inc. (ALGS) has a momentum factor score of 22/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 40/100 reflects moderate short selling activity.

ALGS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Aligos Therapeutics, Inc. (ALGS) ranks #502 out of 838 stocks based on the Blank Capital composite score. This places ALGS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ALGS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALGS vs S&P 500 (SPY) comparison to assess how Aligos Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

ALGS Next Earnings Date

No upcoming earnings date has been announced for Aligos Therapeutics, Inc. (ALGS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ALGS? — Investment Thesis Summary

The quantitative profile for Aligos Therapeutics, Inc. suggests caution. The quality score of 17/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. Momentum is weak at 22/100, a headwind for near-term performance. High volatility (stability score 19/100) increases portfolio risk.

In summary, Aligos Therapeutics, Inc. (ALGS) earns a Reduce rating with a composite score of 21.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALGS stock.

Related Resources for ALGS Investors

Explore more research and tools: ALGS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ALGS head-to-head with peers: ALGS vs AZN, ALGS vs SLGL, ALGS vs VMD.